介入放射学与免疫肿瘤学在肝细胞癌中的交汇
局部和全身治疗是肝细胞癌患者最常用的治疗选择。介入放射科医生改进并开发了用于根治性肿瘤内消融和各种经动脉肝内治疗的方案和器械,持续改善患者结局。两项大型III期随机临床试验已证明不同免疫检查点抑制剂单药或联合一线治疗晚期肝细胞癌的疗效,免疫治疗已成为晚期肝细胞癌的标准一线治疗选择。本文讨论介入放射学(IR)与免疫肿瘤学(IO)领域的进展与前景,总结近期研究结果并概述正在进行的IR与IO研究。基于两个领域的重大进展,作者提出IR与IO需要覆盖新兴的「IR-IO学科」,开发和测试将局部治疗与免疫治疗相结合的新方法,以便在不久的将来为其成为肝细胞癌患者的标准治疗提供充分证据。
要点
- 免疫检查点抑制剂单药或联合一线治疗晚期肝细胞癌的疗效已获两项大型III期随机临床试验证实。
- 免疫治疗已成为晚期肝细胞癌的标准一线治疗选择。
- 作者提出IR与IO需覆盖新兴的「IR-IO学科」,开发并测试局部治疗与免疫治疗相结合的新方法。
核心结论
- 基于IR和IO两个领域的重大进展,作者提出IR和IO需要覆盖新兴的「IR-IO学科」,开发和测试将局部治疗与免疫治疗相结合的新方法,以便在不久的将来为其成为肝细胞癌患者的标准治疗提供充分证据。
研究设计与样本
- 本文为综述,总结近期研究结果并概述正在进行的IR与IO研究。
主要发现
- 两项大型III期随机临床试验已证明不同免疫检查点抑制剂单药或联合一线治疗晚期肝细胞癌的疗效。
- 免疫治疗已成为晚期肝细胞癌的标准一线治疗选择。
- 介入放射科医生改进并开发了用于根治性肿瘤内消融和各种经动脉肝内治疗的方案和器械,持续改善患者结局。
临床怎么用
- 免疫治疗已成为晚期肝细胞癌的标准一线治疗选择。
- 作者提出IR和IO需要覆盖新兴的「IR-IO学科」,开发和测试将局部治疗与免疫治疗相结合的新方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Locoregional and systemic therapies are the most used treatment options for patients with hepatocellular carcinoma (HCC). Interventional radiologists have improved and developed novel protocols and devices for both intratumoural ablative approaches with curative intent and various transarterial intrahepatic treatment options, which have continuously improved patient outcomes. Two large phase III randomised clinical trials have demonstrated the efficacy of different immune checkpoint inhibitors either as single agents or in combination in the first-line setting and immunotherapy has become the standard first-line treatment option for patients with advanced HCC. Herein, we discuss advances and perspectives in the area of interventional radiology (IR) and immune-oncology (IO). We summarise results from recent studies and provide an overview of ongoing studies in IR and IO. Based on the significant advances in both areas, we propose that IR and IO need to cover the emerging "discipline" of IR-IO, in which we develop and test novel approaches to combine locoregional therapies with immunotherapy, in order to develop sufficient evidence for them to be considered standard of care for patients with HCC in the near future.
引用
- Salem R, Greten TF. Interventional radiology meets immuno-oncology for hepatocellular carcinoma. J Hepatol. 2022. PMID: 35988688. doi:10.1016/j.jhep.2022.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。